TITLE

Mitoxantrone helps decrease pain of PCa

PUB. DATE
October 1996
SOURCE
Urology Times;Oct96, Vol. 24 Issue 10, p40
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that the US Food and Drug Administration has recommended for approval mitoxantrone from Immunex for use in hormone-resistant prostate cancer.
ACCESSION #
9610314602

 

Related Articles

  • Drug relieves pain from hormone-refractory PCa.  // Urology Times;Apr97, Vol. 25 Issue 4, p61 

    Features injection concentrate of mitoxantrone, a chemotherapy agent to treat hormone-refractory prostate cancer from Immunex Corp.

  • Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study. Kaliks, Rafael; Guerra, Camila; Del Giglio, Auro // Einstein (16794508);Jul2010, Vol. 8 Issue 3, p336 

    Objective: To evaluate the efficacy and toxicity of the association of mitoxantrone and oral etoposide. Methods: Twelve consecutive patients with metastatic hormone-refractory prostate cancer were treated with mitoxantrone and oral etoposide. Toxicity, response rate and response duration were...

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. Tannock, Ian F.; de Wit, Ronald; Berry, William R.; Horti, Jozsef; Pluzanska, Anna; Chi, Kim N.; Oudard, Stephane; Théodore, Christine; James, Nicholas D.; Turesson, Ingela; Rosenthal, Mark A.; Eisenberger, Mario A. // New England Journal of Medicine;10/7/2004, Vol. 351 Issue 15, p1502 

    Background: Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. Methods: From March 2000 through...

  • Mitoxantrone: a new anticancer drug with significant clinical activity. Shenkenberg, Todd D.; Von Hoff, Daniel D.; Shenkenberg, T D; Von Hoff, D D // Annals of Internal Medicine;Jul86, Vol. 105 Issue 1, p67 

    Clinical studies using mitoxantrone, an anthraquinone, were begun in the United States in 1979. Subsequent phase II and III trials have shown that mitoxantrone has significant clinical activity in patients with breast cancer, acute leukemia, and lymphoma. The drug has antiviral, antibacterial,...

  • Immunosuppression.  // Multiple Sclerosis (13524585);Sep2007 Supplement 2, Vol. 13, pS240 

    The article presents abstracts of medical research which include "Efficacy and safety of mitoxantrone in multiple sclerosis patients with different clinical courses," "Retrospective study to assess the effectiveness and safety profile of mitoxantrone in a Spanish cohort of multiple sclerosis...

  • Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis. Zaffaroni, Mauro; Rizzo, Annalisa; Baldini, Silvana; Ghezzi, Angelo; Comi, Giancarlo // Neurological Sciences;Sep2008 Supplement 2, Vol. 29, p230 

    We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-β (IFN-β) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/ persistently active...

  • Advanced PCa agent prolongs progression-free survival. Gebhart, Fred // Urology Times;May2011, Vol. 39 Issue 5, p10 

    The article presents information on the phase III prostate cancer clinical trial where the effective use of cabazitaxel noticed 30 percent improvement in survival men of metastatic castration-resistant prostate cancer. Doctor Oliver Sartor reports on the effective use of docetaxel (Taxotere) in...

  • Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS. Sadiq, Saud A.; Rammal, Mustapha; Sara, Gabriel // Multiple Sclerosis (13524585);Mar2008, Vol. 14 Issue 2, p272 

    We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy. Previously only acute forms of leukemia particularly acute promyelocytic leukemia (APL) have been associated with mitoxantrone...

  • Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol. Barbosa Pagnano, Kátia B.; de Carvalho Duarte, Gustavo; Lorand-Metze, Irene; Delamain, Márcia Torresan; Miranda, Eliana Cristina; de Souza, Cármino Antonio // Advances in Hematology;2010, Vol. 2010, p1 

    We analyzed the outcome of a series of 19 newly diagnosed patients with acute promyelocytic leukemia treated with AIDA modified protocol, using mitoxantrone in place of idarubicin. Eleven patients achieved morphologic CR (58%). The remaining 8 patients had induction failure due to death during...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics